Rafferty Asset Management LLC Increased Holdings in Taysha Gene Therapies, Inc.

Summary

Rafferty Asset Management LLC purchased 252,257 shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) worth approximately $436,000 in the fourth quarter. Other institutional investors also increased their holdings in TSHA. Analysts have set a price target for the stock with an average target of $6.57 and a consensus rating of ‘Buy’. TSHA stock opened at $2.85, with a market capitalization of $584.41 million. The previous quarter’s earnings per share were reported as (0.08) dollars.Market Beat

Impact Analysis

The event is classified at the ‘Company Level’ as it pertains specifically to Taysha Gene Therapies, Inc. The purchase of shares by Rafferty Asset Management LLC signals confidence in the company’s future performance, potentially influencing other investors. First-Order Effects include an anticipated positive impact on TSHA’s stock price due to increased demand and the ‘Buy’ consensus rating supporting a bullish outlook. Second-Order Effects might involve broader investor interest in the gene therapy sector if TSHA’s performance aligns with analyst expectations. Investment opportunities lie in considering TSHA stock for portfolios, especially given the disparity between the current stock price ($2.85) and the average price target ($6.57), indicating potential upside.Market Beat